A new study suggests that the immune checkpoint inhibitor, durvalumab, may offer new treatment options for patients living with small cell lung cancer (SCLC). However, its cost raises questions about ...

Scientists from A*STAR Institute of Molecular and Cell Biology (A*STAR IMCB) have identified why certain lung cancer cells ...

Imdelltra demonstrated superior overall survival and progression-free survival compared to standard chemotherapy in ES-SCLC patients post-platinum-based treatment. The DeLLphi-304 trial showed a ...

Frontline: Surgery to remove the tumor is often considered, sometimes followed by chemotherapy or radiation to reduce ...

Despite a significant 48.8% objective response rate and breakthrough therapy status, this regulatory shift reverses years of ...

Clinical predictors of response to immunotherapy in patients with extensive-stage small cell lung cancer. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This abstract does not ...

This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This abstract does not include a full text component.

Adding immunotherapy to chemotherapy before surgery for patients with operable non-small cell lung cancer—the leading cause of cancer deaths worldwide—improved long-term survival overall compared with ...

Roche said Tecentriq combined with lurbinectedin shows significant survival benefits for patients with extensive-stage small cell lung cancer. The Swiss pharmaceutical company said Tuesday that ...

A recent study has analyzed the relationship between different air pollutants and the main subtypes of lung cancer.

When lung cancer treatment stops working, what happens next? New research reveals the answer may depend on how the cancer grows.

Survivors of non-small cell lung cancer are at risk for both second primary lung cancers as well as non-lung secondary ...